Upcoming Events
Friday, September 12, 2025
6:30–9:30 PM
Jaleo by Jose Andres (Disney Springs)
1482 E Buena Vista Drive Orlando, FL 32836
Ticket Price: $175
Join us at Jaleo by José Andrés in Disney Springs for an unforgettable sit-down dinner featuring exquisite Spanish cuisine, signature cocktails, and special guests. This inspiring evening will celebrate the CAP Foundation’s impact, from providing free cancer screenings through See, Test & Treat to advancing global pathology initiatives and supporting the next generation of pathologists through medical student awards.
Reserve your seat and be part of the magic!
This event is sponsored by Lilly, A Medicine Company, and will take place as part of CAP25, the CAP’s annual meeting.
Upcoming Webinars
Innovative Approaches in Cervical Cancer Screening: Extended Genotyping and Self-Collection with BD Onclarity™ HPV Assay
Thursday, May 22, 2025
11:00am – 12:00pm CST
The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued new guidelines reflecting the importance of extended genotyping in HPV testing to support an enhanced standard of patient care.
BD Onclarity™ HPV Assay is the first FDA-approved HPV assay that individually identifies 6 genotypes to be cited in guidelines for the clinical management of a positive HPV test result, also offering the option of self-collection in a healthcare setting.
Join us for a 60-minute webinar, exploring the role self-collection in a healthcare setting and extended genotyping, focusing on the new ASCCP HPV Testing Guidelines, reporting and relevance of extended genotyping results.
You’ll learn about:
- Extended genotyping, its importance in providing enhanced patient care and result reporting.
- How to correctly code to capture the new reimbursement rate associated with HPV tests that incorporate extended genotyping.
- Self-collection in a healthcare setting and associated workflows.
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care.
Health economic and reimbursement information provided by BD is gathered by third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. BD encourages providers to submit accurate and appropriate claims for services. It is always the provider’s responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges and modifiers for services that are rendered. BD recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. BD does not promote the use of its products outside the FDA-cleared or FDA-market authorized labels.
The information presented represents the opinion of the presenters and is not necessarily the view of the CAP Foundation. CAP Foundation does not endorse any products or services mentioned during this webinar. The webinar is possible through a sponsorship from Becton-Dickinson (BD). This activity is not available for CME.
Past Webinars
The clinical utility of NGS panel testing: Identifying PIK3CA, AKT1, and/or PTEN-altered HR+/HER2- advanced breast cancer that may be eligible for treatment with TRUQAP™ (capivasertib) + fulvestrant following progression on or after ET ± CDK4/6i*1
Tuesday, May 21, 2024
11:00 AM–Noon (CT)
Webinar
Learning Objectives
Attending this session will enable learners to:
- Understand the importance of the PI3K/AKT/PTEN pathway in HR+/HER2- locally advanced and metastatic breast cancer following progression on or after endocrine therapy ± CDK4/6i
- Identify the actionable biomarkers in the PI3K/AKT/PTEN pathway by next-generation sequencing (NGS) testing
- Recognize the clinical advancements in HR+/HER2- locally advanced and metastatic breast cancer, including TRUQAP + fulvestrant and the CAPItello-291 study (overview, results, and adverse reactions)
- Understand the role of the pathologists in molecular biomarker testing
Description
Hyperactivation of the PI3K/AKT/PTEN pathway is a key driver behind resistance to endocrine therapy in HR+/HER2- breast cancers.1 Activating mutations in PIK3CA and AKT1, and loss-of-function of PTEN occur in up to 50% of HR+ breast cancer cases.2 NGS panel testing provides comprehensive information on PIK3CA, AKT1, and PTEN alterations status and may indicate eligibility for treatment with TRUQAP, combined with fulvestrant in locally advanced or metastatic breast cancer (aBC/mBC) with one or more PIK3CA, AKT1, and/or PTEN alteration following progression on or after endocrine-based regimen.3
TRUQAP is an oral, pan-AKT kinase inhibitor, that in pre-clinical models targets AKT and blocks amplified signaling driven by PIK3CA, AKT1, and/or PTEN gene alterations, inhibiting tumor growth.3,4 NGS panel testing is rapidly becoming an important tool to help pathologists and other healthcare providers to make well-informed breast cancer management decisions.
This comprehensive short course aims to support pathologists in understanding the importance of the PI3K/AKT/PTEN pathway in HR+/HER2- aBC and identifying all the actionable biomarkers in this pathway via NGS panel testing.
This presentation provides an introduction to TRUQAP and a deep dive into NGS panel testing, highlighting the importance of biomarker testing and providing an overview of guideline recommendations, helping you to take a proactive approach in advocating for NGS panel testing for all patients with aBC.
The information presented represents the opinion of the presenters and is not necessarily the view of CAP Foundation. CAP Foundation does not endorse the products or services. The webinar is possible through a sponsorship from AstraZeneca. This activity is not available for CME.
Presenters
Fresia Pareja, MD, PhD
Pathologist, specializing in Breast Pathology,
Memorial Sloan Kettering Cancer Center
Erika P. Hamilton, MD
Director, Breast Cancer Research Program and Gynecologic Cancer Research Program,
Sarah Cannon Research Institute
Presenters were compensated for their time.
IMPORTANT PRODUCT INFORMATION
Select Safety Information About TRUQAP™ (capivasertib) tablets
TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.
Serious adverse reactions can include hyperglycemia, diarrhea, and cutaneous adverse reactions. May cause fetal harm when administered to pregnant women. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), nausea and fatigue (35% each), increased fasting glucose (37%), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).
Indication and Usage
TRUQAP in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Please see full Prescribing Information, including Patient Information for TRUQAP.
This information is intended for US Healthcare Professionals only
*Following disease progression on or after endocrine therapy. Advanced breast cancer is defined as locally aBC and mBC
aBC, locally advanced breast cancer; AKT, serine/threonine protein kinase; AKT1, serine/threonine protein kinase 1; CDK4/6i, cyclin‐dependent kinase 4/6 inhibitor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; NGS, next-generation sequencing; PI3K, phosphoinositide 3-kinase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN, phosphatase and tensin homolog.
References
- Li H, et al. Cancers (Basel). 2021;13(14):3517.
- Martorana F, et al. Front Pharmacol. 2021;12:662232.
- TRUQAP™ (capivasertib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.
- Ribas R, et al. Mol Cancer Ther. 2015;14(9):2035-2048.
TRUQAP is a trademark of the AstraZeneca group of companies.
US-84203 Last Updated 4/24